SLC5A2 and heart failure: Despite their effect proven in several studies on mortality and rehospitalization in heart failure [25, 26], we noted a reduced prescription of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) or Sacubitril/Valsartan.